Remove case-study-mhra-and-astrazeneca
article thumbnail

Novartis’ Pluvicto presents survival benefit for castration-resistant prostate cancer

pharmaphorum

It has been announced today that Novartis’ Pluvicto (lutetium vipivotide tetraxetan) has shown statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).